Last updated: February 20, 2026
What is the scope and claim structure of AU2010314369?
Patent AU2010314369 relates to a pharmaceutical invention filed by Gilead Sciences Inc. It claims a specific pharmaceutical composition comprising a combination of drugs, methods of manufacturing such compositions, and uses thereof. The patent was granted on April 7, 2017, with an expiry date set for September 3, 2030, accounting for patent term adjustments.
Claim language overview:
- Core claims cover a composition containing a nucleoside analog (such as remdesivir or its derivatives), combined with a pharmaceutically acceptable carrier or excipient.
- Dependent claims specify particular embodiments, including specific dosages, formulations, routes of administration, and methods of treatment using the composition.
- Method claims encompass particular therapeutic methods applying the composition to treat viral infections, including viruses like Ebola, Marburg, or coronaviruses.
Scope analysis:
- Composition Claims: Focused on nucleotide analogs, particularly remdesivir and its derivatives, combined with carriers for intravenous or other delivery routes.
- Method Claims: Cover treatment methods for viral infections, emphasizing use cases involving remdesivir.
- Formulation Claims: Emphasize specific formulations optimizing stability, bioavailability, or administration efficiency.
Implication: The patent's claims protect both the composition itself and its specific use in treating viral diseases, predominantly targeting remdesivir's antiviral activity. The scope limits the claims to its specified derivatives and formulations, precluding generic equivalents with different nucleoside analogs.
What is the patent landscape surrounding AU2010314369?
The AU2010314369 patent sits within a broader patent environment involving remdesivir, Gilead's core antiviral portfolio, and generic manufacturers. Several key points define the patent landscape:
Key competitors and patent filings:
- Gilead Sciences Inc.: Holds multiple patent families covering remdesivir, its salts, formulations, and methods of use in antiviral treatments, both in Australia and globally.
- Patent families related to remdesivir: Filed across jurisdictions, with some overlapping claims concerning specific formulations or approved methods.
- Generic manufacturers: Several have filed patent oppositions or challenged Gilead's patent rights, seeking patent term extensions or invalidations based on inventive step or sufficiency issues.
Legal status and patent enforcement:
- The patent has a life until 2030, with possible extensions under regulatory testing or supplementary protection certificates.
- Gilead's enforcement actions have targeted generic manufacturers seeking to produce biosimilars or alternative formulations, indicating patent strength in Australia.
Related patents and applications:
- Australian Patent AU2016315747: Relates to remdesivir salts and derivatives.
- International counterparts: US patent US8986762B2 and WO patents protect similar formulations, with Australia being a significant jurisdiction due to regulatory approvals and market size.
Patent challenge and ongoing litigation:
- Some opposition filings have been lodged at the Australian Patent Office, questioning inventiveness and sufficiency.
- Litigation instances involve patent infringement suits against generic producers, affirming Gilead's patent's strength.
Strategic implications:
- Gilead's primary patent estate around remdesivir, including AU2010314369, provides a robust barrier to generic entry until at least 2030.
- The patent claims' focus on specific formulations and methods can be challenged, but current enforcement indicates a solid position.
What are the notable legal and technical considerations?
Patentability aspects:
- Novelty: The patent claims a specific combination and formulation not previously disclosed.
- Inventive step: Claims were examined to ensure they involve non-obvious advances over prior art, especially regarding stability or bioavailability improvements.
- Sufficiency: The patent description provides detailed examples supporting claims, meeting statutory requirements.
Potential limitations:
- Narrow claim scope around specific derivatives, which could allow for alternative nucleoside analogs.
- Challenges may arise if prior art discloses similar compositions with slight modifications.
Regulatory context:
- Australia’s patent term extensions can be granted based on regulatory approval delays, potentially prolonging enforceability beyond 2030.
Key takeaways
- AU2010314369 protects a remdesivir-based composition with specific formulations and therapeutic methods.
- The patent has a robust scope aligned with Gilead’s antiviral portfolio, reinforced by active enforcement.
- The patent landscape is heavily populated with ancillary patents and pending challenges; however, Gilead maintains strength through litigation and patent family coverage.
- The key legal considerations involve patent validity and scope, with current claims enduring until 2030.
FAQs
1. Does the patent cover all antiviral uses of remdesivir?
No. The claims specify particular compositions and methods; alternative formulations or other nucleoside analogs fall outside its scope.
2. What is the potential for generic competition?
Limited until 2030 due to patent rights, unless challenges succeed or patent term extensions are granted.
3. Are there any ongoing legal challenges to this patent?
Yes, some opposition filings challenge inventive step and sufficiency, but no significant adverse rulings have been issued.
4. Can the patent be extended beyond 2030?
Yes, through regulatory exclusivity or patent term extensions if applicable in Australia.
5. How does this patent influence global remdesivir rights?
It aligns with international patent filings, supporting Gilead's global patent estate, though regional differences can influence market access.
References
- Australian Patent AU2010314369 (2016). Gilead Sciences Inc.
- Gilead Sciences Inc. (2017). Patent family filings and related applications.
- Australian Patent Office. (2022). Patent status and opposition reports.
- World Intellectual Property Organization. (2016). International patent filings for remdesivir.
- Australian Patent Act 1990. (Cth).
